Trial · NCT03019406
Adverse events1,064
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,064
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Lymph Node Pain | Blood and lymphatic system disorders | PAP: Cohort 1: Avalglucosidase Alfa 20 mg/kg | 0 | 6 | 0 |
| other | Lymph Node Pain | Blood and lymphatic system disorders | PAP: Cohort 2: Avalglucosidase Alfa 40 mg/kg | 0 | 5 | 0 |
| other | Lymph Node Pain | Blood and lymphatic system disorders | PAP: Cohort 3a: Avalglucosidase Alfa 40 mg/kg | 0 | 5 | 0 |
| other | Lymph Node Pain | Blood and lymphatic system disorders | PAP: Cohort 3b: Alglucosidase Alfa | 0 | 6 | 0 |
| other | Lymph Node Pain | Blood and lymphatic system disorders | ETP: Avalglucosidase Alfa 20 mg/kg | 1 | 6 | 1 |
| other | Lymph Node Pain | Blood and lymphatic system disorders | Pooled Arm ETP: Avalglucosidase Alfa 40 mg/kg | 0 | 10 | 0 |
| other | Lymph Node Pain | Blood and lymphatic system disorders | Alglucosidase Alfa in PAP Then Avalglucosidase Alfa 40 mg/kg in ETP | 0 | 3 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | PAP: Cohort 1: Avalglucosidase Alfa 20 mg/kg | 0 | 6 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | PAP: Cohort 2: Avalglucosidase Alfa 40 mg/kg | 1 | 5 | 1 |
| other | Neutropenia | Blood and lymphatic system disorders | PAP: Cohort 3a: Avalglucosidase Alfa 40 mg/kg | 0 | 5 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | PAP: Cohort 3b: Alglucosidase Alfa | 0 | 6 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | ETP: Avalglucosidase Alfa 20 mg/kg | 0 | 6 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | Pooled Arm ETP: Avalglucosidase Alfa 40 mg/kg | 0 | 10 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | Alglucosidase Alfa in PAP Then Avalglucosidase Alfa 40 mg/kg in ETP | 0 | 3 | 0 |
| other | Pericardial Effusion | Cardiac disorders | PAP: Cohort 1: Avalglucosidase Alfa 20 mg/kg | 1 | 6 | 1 |
| other | Pericardial Effusion | Cardiac disorders | PAP: Cohort 2: Avalglucosidase Alfa 40 mg/kg | 0 | 5 | 0 |
| other | Pericardial Effusion | Cardiac disorders | PAP: Cohort 3a: Avalglucosidase Alfa 40 mg/kg | 0 | 5 | 0 |
| other | Pericardial Effusion | Cardiac disorders | PAP: Cohort 3b: Alglucosidase Alfa | 0 | 6 | 0 |
| other | Pericardial Effusion | Cardiac disorders | ETP: Avalglucosidase Alfa 20 mg/kg | 0 | 6 | 0 |
| other | Pericardial Effusion | Cardiac disorders | Pooled Arm ETP: Avalglucosidase Alfa 40 mg/kg | 0 | 10 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03019406/events